SEC Form 4 · accession 0000911916-16-000596
CoLucid Pharmaceuticals, Inc. · CLCD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Raymond Skwierczynski
Officer — Head,Pharmaceutical Operations
Period of report
Jun 10, 2016
Accepted (ET)
Jun 22, 2016 · 5:58 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001348649
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3 | Jun 10, 2016 | S | 508 | $6.5984 | D | 3,753 | D | |
| Common StockF1 | Jun 20, 2016 | S | 500 | $7.00 | D | 3,253 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Securities sold pursuant to a written plan intended to comply with Rule 10b5-1(c)(i) adopted by Mr. Skwierczynski on June 1, 2016.
- F2Represents the sale of 508 shares in multiple transactions, ranging in price from $6.60 to $6.5001 per share, resulting in a weighted average sale price of $6.5984. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price within the range.
- F3Includes 4,261 shares acquired under the CoLucid Pharmaceuticals, Inc. Employee Stock Purchase Plan between December 1, 2015 and May 31, 2016 of which 508 shares were sold on June 10, 2016.